Steris ( (STE) ) has released its Q2 earnings. Here is a breakdown of the information Steris presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
STERIS plc is a global leader in providing innovative healthcare and life science products and services, focusing on infection prevention to support patient care worldwide. The company operates primarily in the healthcare sector, offering a range of products and services aimed at creating a healthier and safer world.
In its fiscal 2026 second quarter, STERIS reported a robust financial performance with a 10% increase in total revenue from continuing operations, reaching $1.5 billion. The company’s earnings per share (EPS) also saw significant growth, with reported EPS rising to $1.94 and adjusted EPS increasing to $2.47. This strong performance has led the company to raise its outlook for fiscal 2026.
Key financial highlights include a 9% growth in healthcare revenue, driven by improvements in service, consumable, and capital equipment revenues. The Applied Sterilization Technologies segment also saw a 10% revenue increase, despite a decline in capital equipment revenue. The Life Sciences segment experienced a 13% revenue growth, primarily due to a substantial increase in capital equipment revenue. Overall, the company’s net income from continuing operations rose to $191.9 million, reflecting improved volume, pricing, and productivity.
STERIS’s cash flow also showed positive trends, with net cash provided by operations reaching $707.8 million for the first half of fiscal 2026, up from $554.4 million in the previous year. Free cash flow increased significantly to $527.7 million, driven by earnings growth and working capital improvements.
Looking ahead, STERIS has increased its fiscal 2026 outlook, expecting revenue from continuing operations to grow by 8-9%. The company anticipates adjusted EPS to be in the range of $10.15 to $10.30, reflecting confidence in its strategic initiatives and operational efficiencies, despite challenges such as tariffs and inflation.